Verzenio (abemaciclib) is a brand-name oral tablet prescribed for certain forms of breast cancer. Verzenio has interactions with certain other drugs, some foods, and certain supplements. Examples ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

Verzenio (abemaciclib ... abemaciclib orally twice a day on a continuous dosing schedule, every 12 hours or 150 mg of Tarceva administered at its approved dose and schedule until disease ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...